Analysis of dose comparison techniques for patient-specific quality assurance in radiation therapy

Liting Yu1,2 | Timothy L. S. Tang2,3 | Naasiha Cassim1 | Alexander Livingstone1 | Darren Cassidy1 | Tanya Kairn1,2 | Scott B. Crowe1,2

1Royal Brisbane and Women’s Hospital, Herston, Qld., Australia
2Queensland University of Technology, Brisbane, Qld., Australia
3Beacon International Specialist Centre, Petaling Jaya, Malaysia

Author to whom correspondence should be addressed. Liting Yu
E-mail: nancy.yu@health.qld.gov.au

Abstract

Purpose: Gamma evaluation is the most commonly used technique for comparison of dose distributions for patient-specific pretreatment quality assurance in radiation therapy. Alternative dose comparison techniques have been developed but not widely implemented. This study aimed to compare and evaluate the performance of several previously published alternatives to the gamma evaluation technique, by systematically evaluating a large number of patient-specific quality assurance results.

Methods: The agreement indices (or pass rates) for global and local gamma evaluation, maximum allowed dose difference (MADD) and divide and conquer (D&C) techniques were calculated using a selection of acceptance criteria for 429 patient-specific pretreatment quality assurance measurements. Regression analysis was used to quantify the similarity of behavior of each technique, to determine whether possible variations in sensitivity might be present.

Results: The results demonstrated that the behavior of D&C gamma analysis and MADD box analysis differs from any other dose comparison techniques, whereas MADD gamma analysis exhibits similar performance to the standard global gamma analysis. Local gamma analysis had the least variation in behavior with criteria selection. Agreement indices calculated for 2%/2 mm and 2%/3 mm, and 3%/2 mm and 3%/3 mm were correlated for most comparison techniques.

Conclusion: Radiation oncology treatment centers looking to compare between different dose comparison techniques, criteria or lower dose thresholds may apply the results of this study to estimate the expected change in calculated agreement indices and possible variation in sensitivity to delivery dose errors.

Key Words
dose comparison technique, gamma evaluation, PSQA, radiation therapy

1 | INTRODUCTION

Patient-specific pretreatment quality assurance (PSQA) tests are routinely performed for the verification of modulated radiation therapy treatment delivery. Modulated treatment modalities, including intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT) and helical tomotherapy (HT), achieve highly conformal dose distributions by optimization of dose rates and multi-leaf collimator (MLC) gantry, couch and collimator movements. The complexity of MLC movement and the treatment planning system...
(TPS) dose calculation limitations (accuracy of beam modeling and the algorithm itself) are two of the multiple factors that can introduce disagreement between planned and delivered dose, which impact the accuracy of treatment delivery.

The most common form of PSQA involves the comparison of TPS dose calculations with 2D or 3D dose measurements.\(^3\)\(^-\)\(^5\) The gamma evaluation method (also known as gamma analysis, or gamma index analysis), developed by Low et al.\(^6\)\(^,\)\(^7\) is widely used to compare such measurements.\(^5\) This technique compares an evaluated (usually measured) dose distribution with a reference (usually calculated) dose distribution in a quantitative manner by calculating the gamma value of each point, which is the minimum Euclidean distance in the dose-spatial domain. The agreement between evaluated and reference dose distributions is calculated using two acceptance criteria: dose difference, \(\Delta D\), in %; and distance-to-agreement, DTA, in mm. Gamma analysis produces gamma index values assigned to each individual point, for which gamma index values \(\leq 1\) indicate passed or otherwise failed. The percentage of passing points in the gamma distribution is referred to as gamma pass rate (or %GP). %GP can be used by the users to establish or apply action levels. Surveys of PSQA practices have reported that \(\Delta D\) and DTA criteria of 3%/3 mm are the most frequently used.\(^2\)\(^-\)\(^4\)

Global gamma evaluation normalizes the percent differences for every point to a globally used single value, usually the maximum planned dose; whilst local gamma evaluation normalizes the percent differences for every point to the expected dose at each point. Thus, the %GP calculated by global gamma will always be higher than or equal to local gamma, where the same criteria and lower dose threshold are used.\(^5\) The use of global gamma evaluation for PSQA using \(\Delta D\) and DTA criteria of 3%/3 mm has been questioned due to reported poor sensitivity and specificity to delivery errors\(^9\)\(^-\)\(^15\) and clinically relevant patient dose errors.\(^11\)\(^-\)\(^16\)\(^,\)\(^17\) and a lack of clinical intuitiveness.\(^17\)\(^,\)\(^18\) Some authors have proposed DVH-based QA metrics as a response to these criticisms.\(^17\) A number of studies have proposed or evaluated alternative dose comparison techniques, or assessed variation in behavior of gamma evaluation for both local and global gamma evaluations with different criteria and lower dose thresholds (LDT).\(^19\)\(^,\)\(^20\)

Jiang et al.\(^18\) proposed the maximum allowed dose difference (MADD) technique, in which a distance-to-agreement criterion is converted to a dose difference by multiplying the dose gradient at the point of interest. This DTA-equivalent dose criteria is combined with \(\Delta D\) to determine MADD (by summation for box calculation MADD\(_b\), or summation in quadrature for gamma calculation MADD\(_g\)). The difference between dose distributions at the point of interest can then be normalized by local MADD (as a “normalised dose difference”), providing an index in which values \(\leq 1\) indicate agreement. The advantage of this method over the gamma method is that it is not only accurate and simple but also clinically intuitive and insensitive to dose grid resolution.

Stojadinovic et al.\(^14\) proposed the divide and conquer (D&C) gamma method, in which the determination of agreement between dose distributions is dependent on the dose region: a high dose (HD) region within the 90% isodose, a high gradient (HG) region between the 90% and 50% isodoses, a medium dose (MD) region between the 50% and 20% isodoses, and a low dose (LD) region between 20% to 10% isodoses. Significant differences in behavior were reported, when D&C results were compared to conventional gamma evaluation, for a dataset containing 50 PSQA measurements.\(^14\) This method has challenged the adequacy of conventional IMRT QA programs. The authors concluded that a better paradigm would be needed to standardize IMRT QA practices. The advantage of the D&C method over the gamma method is that by analyzing four distinct regions separately, more reasonable characterization of the agreement between calculations and measurements can be performed without combining regions of high and low dose gradients.

Some studies have analyzed the effect of induced error to the PSQA results using gamma method.\(^21\)\(^,\)\(^22\) Other studies have characterized the effect of \(\Delta D\) and DTA criteria selection on gamma agreement indices. Crowe et al.\(^23\) reported that global gamma agreement indices calculated using 2%/3 mm, 3%/2 mm, and 3%/3 mm were correlated with each other, suggesting that these criteria would produce similar PSQA results (or similar sensitivity and specificity), if action thresholds were adjusted accordingly. Recommendations were provided for radiation oncology treatment centers intending to transition to tighter global gamma evaluation \(\Delta D\) and DTA criteria.\(^23\)

However, although optimal gamma parameters and performance of alternative metrics were tested in the literature\(^19\)\(^,\)\(^20\)\(^,\)\(^24\) few studies\(^8\) have provided suggestions to radiation oncology treatment centers looking to compare between these alternative dose comparison techniques, between different \(\Delta D\) and DTA criteria pairs (for local gamma evaluation techniques) or LDT. This study evaluated the D&C, MADD, local and global gamma dose comparison techniques across a variety of agreement criteria and LDT, for 429 existing PSQA measurements obtained using ArcCheck helical diode array (Sun Nuclear Corporation, Melbourne, FL), including 57 beams that failed departmental quality assurance tests, for both HT and VMAT treatments. The percentage of failed plans included in this study is approximately the same as in actual clinical occurrence. A “failed” plan is defined simply by the numerical pass rate and our institutional acceptance criteria: most “failed” plans in this study were considered clinically acceptable when reviewed by a Radiation Oncologist.

## 2 | MATERIALS AND METHODS

The global gamma analysis, local gamma analysis, D&C and MADD methods were implemented in Matlab version R2015b (MathWorks, Massachusetts, USA), per original descriptions by Low et al.\(^6\)\(^,\)\(^7\) Stojadinovic et al.\(^14\) and Jiang et al.\(^18\) respectively. The implementation of the gamma analysis and MADD methods was validated using data described by Low and Dempsey.\(^7\)\(^,\)\(^18\)

The in-house software was designed to iterate through routinely prepared PSQA directories, containing TPS calculated dose distributions, converted to the “.snc” format using Sun Nuclear SNC Patient
An overview of the QA measurements selected for this study is shown in Table 1. This cohort included both measurements that passed departmental PSQA and those that failed. The passed measurements are those that produce global %GPs ≥95% at 2%/2 mm and LDT of 5% with Measurement Uncertainty Corrections turned on in the SNC Patient Software. The Measurement Uncertainty Correction is a default option in the SNC Patient Software intended to compensate for presumed sources of measurement uncertainty that potentially decrease the calculated pass rate. It typically adds about 1%-2% to the user-defined acceptance criterion of percentage difference acceptance tolerance. By applying the Measurement Uncertainty Correction, the user essentially loosens the gamma comparison criteria from 2%/2 mm to 3%/2 mm, which is the recommendation from TG-218. The failed measurements are those that produce global %GPs <95% under the same conditions. Two hundred and sixty two VMAT beams were analyzed, including 230 passed and 32 failed beams. The work was repeated for 167 HT plans, including 142 passed and 25 failed plans (see appendix).

%GPs were calculated using multiple criteria (1%/1 mm, 2%/2 mm, 2%/3 mm, 3%/2 mm, 3%/3 mm, and 5%/3 mm), multiple LDTs (5% and 10%) and with ΔD both determined globally (i.e. using maximum dose value in distribution) and locally. MADDp and MADDd determined agreement indices were calculated using the same criteria pairs as were used for the global and local gamma evaluations. These criteria were selected based on local and survey-reported practices.  

D&C agreement indices were calculated using the same criteria pairs as were used for the gamma and MADD evaluations, with ΔD criteria replaced as summarized in Table 2. The dose criteria for each dose region was selected for approximate equality in terms of dose criteria replaced as summarized in Table 2. The dose criteria for each dose comparison technique are presented as above.

Varying criteria for each dose comparison technique, and calculated using varying dose comparison techniques for each criteria were quantified using ordinary least squares regression. Correlation (or similarity in behavior, in terms of identifying results as demonstrating high or low agreement) was assessed using coefficients of determination R² (representing the variation in the dependent variable that can be explained by variation in the independent variable) and P-values. An R² > 0.64 was selected as a correlation threshold, consistent with the adoption of a Pearson’s correlation coefficient of 0.8 as a minimum clinically acceptable value in the literature.  

When evaluating relationships between comparison techniques and agreement criteria, global and local %GPs were calculated using 10% LDT, the most frequently reported threshold value in the literature.

### RESULTS

This section only included the results from the VMAT plans. The HT results can be found in the appendix. Table 2 shows the mean agreement indices that resulted from evaluating 262 VMAT PSQA measurements using the various comparison methods investigated in this study. Table 4 summarized correlation between 5% and 10% LDT-calculated %GPs for VMAT plans (P > α in all cases). Calculated R² values and Šidák-corrected significance results for relationships between dose comparison techniques for 2%/2 mm are presented in Table 5. Calculated R² values and Šidák-corrected significance results for relationships between agreement indices calculated for varying criteria for each dose comparison technique are presented as appendix.

The following results were observed:

- The mean agreement indices calculated at 5%/3 mm were nearly 100% for every case except for local gamma analysis.

| Table 2 | Dose difference criteria used for D&C evaluation. |
|---------|--------------------------------------------------|
| ΔD (%) | ΔDHD (%) | ΔDHG (%) | ΔDM (%) | ΔDM (%) |
| 1      | 1        | 1.5      | 3       | 6       |
| 2      | 2        | 3        | 5       | 8       |
| 3      | 3        | 4        | 5       | 10      |
| 5      | 5        | 7        | 10      | 15      |

Abbreviation: D&C, divide and conquer.

| Table 1 | Overview of PSQA measurements assessed. |
|---------|----------------------------------------|
| Modality | Accelerator | Beams passed | Beams failed | MLC | TPS | Algorithm |
| HT      | Hi-Art 2   | 142          | 25           | Binary MLC | Tomotherapy | CCC |
| VMAT    | Varian IX | 230          | 32           | Millenium 120 | Eclipse v13.5 | AAA |

Abbreviations: HT, helical tomotherapy; MLC, multileaf collimator; PSQA, patient-specific pretreatment quality assurance; TPS, treatment planning system; VMAT, volumetric modulated arc therapy.
TABLE 3  Mean agreement indices (%) and standard deviation of 262 VMAT arcs for each dose comparison technique.

| Index                   | 1%/1 mm | 2%/2 mm | 2%/3 mm | 3%/2 mm | 3%/3 mm | 5%/3 mm |
|-------------------------|---------|---------|---------|---------|---------|---------|
| γ\textsubscript{global LDT} = 5% | 58.3 ± 9.2 | 94.8 ± 2.9 | 97.3 ± 1.8 | 98.1 ± 2.0 | 99.1 ± 1.1 | 99.8 ± 0.4 |
| γ\textsubscript{global LDT} = 10% | 53.0 ± 9.5 | 93.3 ± 4.1 | 96.6 ± 2.5 | 97.5 ± 2.9 | 98.7 ± 1.6 | 99.8 ± 0.6 |
| γ\textsubscript{local LDT} = 5% | 17.1 ± 6.1 | 60.4 ± 9.0 | 73.3 ± 8.2 | 69.6 ± 9.3 | 79.8 ± 8.1 | 87.4 ± 7.6 |
| γ\textsubscript{local LDT} = 10% | 20.1 ± 6.4 | 69.1 ± 7.5 | 81.5 ± 5.2 | 78.9 ± 7.0 | 87.8 ± 4.5 | 94.4 ± 3.5 |
| D&C                     | 58.5 ± 13.1 | 92.4 ± 7.6 | 95.5 ± 5.1 | 96.4 ± 5.6 | 97.9 ± 3.9 | 99.4 ± 1.9 |
| MADD\textsubscript{b}     | 86.9 ± 9.8  | 99.5 ± 0.6 | 99.8 ± 0.3 | 99.9 ± 0.2 | 100 ± 0.1 | 100 ± 0.03 |
| MADD\textsubscript{y}     | 75.8 ± 14.2 | 97.7 ± 1.6 | 98.9 ± 1.0 | 99.2 ± 0.7 | 99.3 ± 6.1 | 100 ± 0.1 |

Abbreviations: D&C, divide and conquer; LDT, lower dose thresholds; MADD, maximum allowed dose difference; VMAT, volumetric modulated arc therapy.

- Applying more strict gamma criteria results in higher standard deviation of data.
- Global gamma evaluation technique with various gamma criteria behave similarly regardless of LDT.
- The correlation between 5% and 10% LDT in local gamma calculations decreased with increasing ΔD and DTA, suggesting that large percentage dose differences were more prevalent in low dose regions. Local gamma analysis had the least variation in behavior with criteria selection.
- Correlation of 1%/1 mm or 5%/3 mm with other criteria was generally poor for all techniques except local gamma evaluation, where VMAT shows lower correlation than HT (see appendix) at 1%/1 mm. Correlation at 2%/2 mm was generally poor between gamma, D&C and MADD dose comparison techniques in VMAT plans.
- Agreement indices calculated for 2%/2 mm and 2%/3 mm, and 3%/2 mm and 3%/3 mm were correlated for most comparison techniques.

4 | DISCUSSION

The mean %GPs calculated for multiple criteria in this study were consistent with values reported in the literature for VMAT technique. The differences between the global %GP with 5% LDT were consistent with results reported by Crowe et al.\textsuperscript{23} using ArcCheck measurements, particularly at 1%/1 mm.

The behavior of %GP with varying LDT is consistent with results described by Son et al.,\textsuperscript{26} where increasing the LDT resulted in an increase of agreement indices for global gamma evaluation, and a decrease in agreement indices for local gamma evaluation. Choice of LDT may potentially have large a impact on calculated %GP, particularly with stricter agreement criteria, for example, tighter tolerances or local (rather than global) gamma calculation.

The coefficient of determination values in Tables 4 and 5 and the appendix identify whether an agreement index calculated using one technique, criteria pair or LDTs is predictive of the agreement index calculated using a different technique, criteria pair or LDT; or in other words, whether there is consistency in which plans have relatively high or low agreement indices, regardless of the technique, criteria or LDT selection\textsuperscript{23}. A low coefficient of determination (R^2 < 0.64), i.e. poor correlation, suggests that the two dose comparison techniques, criteria pair or LDT exhibit different behaviors, and thus may exhibit different sensitivity to dose errors.

Assuming dose delivery accuracy (or “plan deliverability”) is intrinsic to a treatment plan, it would be reasonable to assume correlation of agreement indices across different criteria. The correlation between agreement indices calculated using local gamma evaluation supports this assumption, and may assist in explaining, for example, why machine learning has been successfully used to predict local gamma evaluation agreement indices from treatment parameters.\textsuperscript{27}

The difference in behavior of local and global gamma evaluation techniques identified here is consistent with observations in the literature,\textsuperscript{11,12} which report that the two techniques exhibit varying specificity and sensitivity to dose delivery errors. Stasi et al.\textsuperscript{11}

TABLE 4  R^2 for relationship between %GPs using 5% LDT and 10% LDT for 262 VMAT arcs.

| Index       | 1%/1 mm | 2%/2 mm | 2%/3 mm | 3%/2 mm | 3%/3 mm | 5%/3 mm |
|-------------|---------|---------|---------|---------|---------|---------|
| γ\textsubscript{global} | 0.702 | 0.947 | 0.955 | 0.980 | 0.983 | 0.985 |
| γ\textsubscript{local} | 0.865 | 0.481 | 0.287 | 0.393 | 0.212 | 0.112 |

Abbreviations: LDT, lower dose thresholds; VMAT, volumetric modulated arc therapy.

TABLE 5  R^2 for relationship between agreement indices for varying dose comparison techniques using 2%/2 mm for 262 VMAT plans.

| Index       | D&C     | MADD\textsubscript{b} | MADD\textsubscript{y} |
|-------------|---------|------------------------|------------------------|
| γ\textsubscript{global} | 0.652 | 0.538 | 0.133 | 0.009 |
| γ\textsubscript{local} | 0.404 | 0.043 | 0.043 | 0.000 |
| D&C         | 0.043 | 0.001 | 0.626 |

Abbreviations: D&C, divide and conquer; MADD, maximum allowed dose difference; VMAT, volumetric modulated arc therapy.
reported improved sensitivity to errors when using local gamma evaluation, compared to global gamma evaluation. Nelms et al.\textsuperscript{12,16} identified the use of global normalization as a contributor to insensitivity to dose errors in anatomic regions-of-interest.

Among the 262 VMAT PSQA measurements analyzed, 32 measurements were included which failed the initial global gamma evaluation using 2%, 2 mm and LDT 5%. The failed plans were selected from our most recent QA records, and their number approximates the same clinical occurrence ratio of failed plans among all PSQA in our clinic. With the inclusion of the failed plans, the overall behavior of the performed analyses is consistent with those with passed plans only. However in Table 5, the correlation may be overestimated due to the much lower pass rates and the low proportion of the failed plans compared with the passed ones, as shown in Fig. 1. The $R^2$ values become less comparable when the sample size varies, therefore cannot be solely relied upon. According to the figure, it also indicated that gamma pass rates of 90% for global gamma falls to an average of approximately 60% when local gamma metric is used.

The search for better dose comparison metrics has been ongoing for years. TG-218\textsuperscript{5} also cited several other tools proposed after the gamma test, including the gradient compensation method,\textsuperscript{28} the normalized agreement test (NAT)\textsuperscript{29} and the Bakai method.\textsuperscript{30} They all pointed out the weaknesses of the gamma test and hence the desire for an improved dose comparison matrix. To a radiation oncology treatment center currently employing the common 3%/3 mm global gamma evaluation technique with 10% LDT,\textsuperscript{2-4} the results of this study demonstrated:

- The expected change in agreement indices for the global gamma evaluation can be estimated if the center adopts a tighter (2%/2 mm) criteria, as recommended by Nelms et al.\textsuperscript{12} (98.7 ± 1.6 to 93.3 ± 4.1).
- The D&C technique or the local gamma evaluation may exhibit increased sensitivity to dose errors\textsuperscript{11,12} and thus may be preferable to identify undesirable plans. According to Table 3, a 1%-10% decrease in pass rate may be expected for the criteria of 3%, 3 mm based on the data presented in this work.

5 | CONCLUSIONS

This work has evaluated alternative dose comparison techniques and compared with the standard gamma analysis technique. It was found that each individual dose comparison technique behaves differently from each other. The local gamma analysis had the strongest correlation between results calculated using different acceptance criteria amongst the dose comparison techniques. Radiation oncology treatment centers looking to compare between different dose comparison techniques, criteria or LDT may use the results of this study to estimate the expected differences in calculated agreement indices and possible variations in behavior to delivery dose errors.

![Fig. 1.](image)
CONFLICT OF INTEREST

The authors have no relevant conflicts of interest to disclose.

REFERENCES

1. Schreibmann E, Dhabaan A, Elder E, Fox T. Patient-specific quality assurance method for VMAT treatment delivery. Med Phys. 2009;36(10):4530–4535.
2. Nelms BE, Simon JA. A survey on IMRT QA analysis. J Appl Clin Med Phys. 2007;8(3):76–90.
3. Abolaban F, Zaman S, Cashmore J, Nisbet A, Clark CH. Changes in patterns of intensity-modulated radiotherapy verification and quality assurance in the UK. Clin Oncol. 2016;28(8):e28–e34.
4. Barber J, Vial P, White P, et al. A survey of modulated radiotherapy use in Australia & New Zealand in 2015. Australas Phys Eng Sci Med. 2017;40(4):811–822.
5. Miften M, Olich A, Mihailidis D, et al. Tolerance limits and methodologies for IMRT measurement-based verification QA: recommendations of AAPM Task Group No. 218. Med Phys. 2018;45(4):e53–e83.
6. Low DA, Harms WB, Mutic S, Purdy JA. A technique for the quantitative evaluation of dose distributions. Med Phys. 1998;25(5):656–661.
7. Low DA, Dempsey JF. Evaluation of the gamma dose distribution comparison method. Med Phys. 2003;30(9):2455–2464.
8. Bailey DW, Nelms BE, Attwood K, Kumaraowamy L, Podgorsak MB. Statistical variability and confidence intervals for planar dose QA pass rates. Med Phys. 2011;38(11):6053–6064.
9. Yan G, Liu C, Simon TA, Peng L-C, Fox C, Li JG. On the sensitivity of patient-specific IMRT QA to MLC position errors. J Appl Clin Med Phys. 2008;10(1):120–128.
10. Kruse JJ. On the insensitivity of single field planar dosimetry to IMRT inaccuracies. Med Phys. 2010;37(8):2516–2524.
11. Stasi M, Bresciani S, Miranță A, Maggio A, Sapino V. Pretreatment patient-specific IMRT quality assurance: A correlation study between gamma index and patient clinical dose volume histogram. Med Phys. 2012;39(12):7626–7634.
12. Nelms BE, Chan MF, Barry G, et al. Evaluating IMRT and VMAT dose accuracy: practical examples of failure to detect systematic errors when applying a commonly used metric and action levels. Med Phys. 2013;40(11):111722.
13. Kim J-I, Park S-Y, Kim HJ, Kim JM, Ye SJ, Park JM. The sensitivity of gamma-index method to the positioning errors of high-definition MLC in patient-specific VMAT QA for SBRT. Radiat Oncol. 2014;9(1):167.
14. Stojadinovic S, Ouyang L, Xuejun G, Pomposi A, Bao Q, Solberg TD. Breaking bad IMRT QA practice. J App Clin Med Phys. 2015;16(3):154–165.
15. Steers JM, Fraass BA. IMRT QA: Selecting gamma criteria based on error detection sensitivity. Med Phys. 2016;43(4):1982–1994.
16. Nelms BE, Zhen H, Tomé WA Per-beam, planar IMRT QA passing rates do not predict clinically relevant patient dose errors. Med Phys. 2011;38(2):1037–1044.
17. Zhen H, Nelms BE, Tomé WA Moving from gamma passing rates to patient DVH-based QA metrics in pretreatment dose QA. Med Phys. 2011;38(10):5477–5489.
18. Jiang SB, Sharp GC, Neicu T, Berbeco RI, Flamponi S, Bartfeld T. On dose distribution comparison. Phys Med Biol. 2006;51(4):759.
19. Garcia-Romero A, Hernandez-Vitoria A, Milan-Cebrian E, Alba-Escorihuela V, Serrano-Zabaleta S, Ortega-Pardina P. On the new metrics for IMRT QA verification. Med Phys. 2016;43(11):6058–6071.
20. McNiven AL, Sharpe MB, Purdie TG. A new metric for assessing IMRT modulation complexity and plan deliverability. Med Phys. 2010;37(2):505–515.
21. Sjölin M, Edmund JM. Incorrect dosimetric leaf separation in IMRT and VMAT treatment planning: Clinical impact and correlation with pretreatment quality assurance. Physica Med. 2015;31(7):918–925.
22. Carlone M, Cruje C, Rangel A, McCabe R, Nielsen M, MacPherson M. ROC analysis in patient specific quality assurance. Med Phys. 2013;40(4):042103.
23. Crowe SB, Sutherland B, Wilks R, et al. Technical note: Relationships between gamma criteria and action levels: Results of a multicenter audit of gamma agreement index results. Med Phys. 2016;43(3):1501–1506.
24. Glenn MC, Hernandez V, Saez J, et al. Treatment plan complexity does not predict IROC Houston anthropomorphic head and neck phantom performance. Phys Med Biol. 2018;63(20):205015.
25. Jin X, Yan H, Han C, Zhou Y, Yi J, Xie C. Correlation between gamma index passing rate and clinical dosimetric difference for pretreatment 2D and 3D volumetric modulated arc therapy dosimetric verification. Br J Radiol. 2015;88(1047):20140577.
26. Son J, Baek T, Lee B, et al. A comparison of the quality assurance of four dosimetric tools for intensity modulated radiation therapy. Radiat Oncol. 2015;49(3):307–313.
27. Valdes G, Scheuermann R, Hung CY, Olszanski A, Bellerive M, Solberg TD. A mathematical framework for virtual IMRT QA using machine learning. Med Phys. 2016;43(7):4323–4334.
28. Moran JM, Radawski J, Fraass BA. A dose-gradient analysis tool for IMRT QA. J Appl Clin Med Phys. 2005;6(2):62–73.
29. Childress NL, Rosen II. The design and testing of novel clinical definitions of interest to disclose.
APPENDIX

Table A1 shows the mean agreement indices that resulted from evaluating 167 HT PSQA measurements using the various comparison methods investigated in this study. There are more spread in the data of HT plans than VMAT ones for all techniques and criteria. For tighter criteria, there are more spread in the data for both treatment modalities.

### TABLE A1 MEAN AGREEMENT INDICES (%) AND STANDARD DEVIATION OF 167 HT PLANS FOR EACH DOSE COMPARISON TECHNIQUE

| Index | 1%/1 mm | 2%/2 mm | 2%/3 mm | 3%/2 mm | 3%/3 mm | 5%/3 mm |
|-------|---------|---------|---------|---------|---------|---------|
| γ<sub>global</sub>LDT=5% | 51.0 ± 16.6 | 91.7 ± 11.8 | 95.1 ± 8.7 | 97.3 ± 5.5 | 98.5 ± 3.6 | 99.8 ± 0.7 |
| γ<sub>global</sub>LDT=10% | 50.8 ± 15.9 | 91.1 ± 12.4 | 94.9 ± 8.9 | 96.9 ± 6.6 | 98.3 ± 4.2 | 99.8 ± 0.9 |
| γ<sub>local</sub>LDT=5% | 18.8 ± 7.2 | 57.8 ± 14 | 71.6 ± 12.8 | 67.3 ± 14.8 | 78.1 ± 12.9 | 85.9 ± 11.6 |
| γ<sub>local</sub>LDT=10% | 20.5 ± 7.2 | 62.7 ± 13.5 | 76.8 ± 11.8 | 72.9 ± 13.9 | 83.4 ± 11.5 | 91.1 ± 9.5 |
| D&C | 57.1 ± 15.0 | 90.2 ± 11.0 | 94.2 ± 8.2 | 95.7 ± 7.1 | 97.6 ± 5.2 | 99.5 ± 1.9 |
| MAD<sub>d</sub> | 76.8 ± 16.7 | 97.6 ± 5.3 | 98.6 ± 3.3 | 99.0 ± 7.1 | 99.7 ± 0.9 | 100 ± 0.1 |
| MAD<sub>D</sub> | 62.8 ± 16.6 | 93.0 ± 10.3 | 95.5 ± 8.1 | 97.8 ± 4.7 | 98.7 ± 3.49 | 9.9 ± 0.5 |

Table A2 summarised correlation between 5% and 10% LDT-calculated gamma agreement indices for HT plans ($p \leq \alpha$ in all cases). For global gamma evaluation, the results of 5% or 10% LDT calculations are correlated for all criteria, i.e. the techniques behave similarly regardless of LDT. For local gamma evaluation, the correlation between 5% and 10% LDT calculations decreased with increasing ΔD and DTA, suggesting that large percentage dose differences were more prevalent in low dose regions. The behaviour variation between HT and VMAT cohorts possibly suggests a difference in low dose calculation or delivery accuracy between the two treatment modalities. (Tables A3 and A4)

Correlation was poor for most relationships in VMAT. Better overall correlation was observed for HT plans, with MAD<sub>d</sub> vs. MAD<sub>D</sub> being the highest (Table A5; Fig A1).

![Global versus Local %GP at 2%, 2mm for VMAT Plans](image1.png)  
![Passed VMAT Plans](image2.png)  
![Failed VMAT Plans](image3.png)  

**Fig. A1.** (a) Global vs. local %GPs at 2%, 2 mm for all HT plans, (b) Global versus local %GPs at 2%, 2 mm for passed HT plans, and (c) Global versus local %GPs at 2%, 2 mm for failed HT plans.
### Table A2 \( R^2 \) for Relationship Between %GP Using 5% LDT and 10% LDT for 167 HT Plans

| Index | 1%/1 mm | 2%/2 mm | 2%/3 mm | 3%/2 mm | 3%/3 mm | 5%/3 mm |
|-------|---------|---------|---------|---------|---------|---------|
| \( \gamma_{\text{global}} \) | 0.982   | 0.981   | 0.983   | 0.975   | 0.982   | 0.987   |
| \( \gamma_{\text{local}} \)  | 0.973   | 0.926   | 0.884   | 0.920   | 0.878   | 0.845   |

### Table A3 \( R^2 \) for Relationship Between Agreement Indices for Varying Dose Comparison Techniques Using 2%/2 mm for HT (Lower Left, Shaded) and VMAT (Upper Right)

|          | \( \gamma_{\text{global}} \) | \( \gamma_{\text{local}} \) | D&C    | MADD_b | MADD_\gamma |
|----------|-------------------------------|-------------------------------|--------|--------|-------------|
| \( \gamma_{\text{global}} \) | 0.652                         | 0.538                         | 0.133  | 0.009  |             |
| \( \gamma_{\text{local}} \)  | 0.680                         | 0.404                         | 0.043  | 0      | 0.001       |
| D&C      | 0.868                         | 0.652                         |        |        | 0.626       |
| MADD_b   | 0.844                         | 0.567                         | 0.717  |        |             |
| MADD_\gamma | 0.874                       | 0.627                         | 0.751  | 0.943  |             |

**Notes**

\( \alpha_{\text{sid}} \) corrected significance level \( \alpha_{\text{sid}} = 0.003 \), \( p_{\text{sid}} \) in all cases except for HT where MADD_\gamma: \( p_{\text{sid}} \) (2%/2 mm vs. 3%/2 mm) = 0.039, MADD_b: \( p_{\text{sid}} \) (2%/3 mm vs. 3%/3 mm) = 0.586, MADD_b: \( p_{\text{sid}} \) (3%/2 mm vs. 3%/3 mm) = 0.152, MADD_b: \( p_{\text{sid}} \) (3%/2 mm vs. 5%/3 mm) = 0.062 and VMAT where MADD_\gamma: \( p_{\text{sid}} \) (2%/3 mm vs. 3%/3 mm) = 0.326, MADD_\gamma: \( p_{\text{sid}} \) (3%/2 mm vs. 3%/3 mm) = 0.863, MADD_\gamma: \( p_{\text{sid}} \) (3%/3 mm vs. 5%/3 mm) = 0.087.

### Table A4 \( R^2 \) for Relationship Between %GP/BAI Using One Pair of Particular Criteria and Other Pairs of Criteria. Tomotherapy Results in Lower Left, VMAT Results in Upper Right

| Colour    | HT          | VMAT        |
|-----------|-------------|-------------|
| \( \gamma_{\text{global}} \) | 1%/1 mm     | 2%/2 mm     | 2%/3 mm | 3%/2 mm | 3%/3 mm | 5%/3 mm |
|          | 0.628       | 0.474       | 0.500   | 0.407   | 0.305   | 0.474   |
|          | 2%/2 mm     | 0.760       | 0.860   | 0.897   | 0.769   | 0.567   |
|          | 2%/3 mm     | 0.682       | 0.967   | 0.812   | 0.840   | 0.606   |
|          | 3%/2 mm     | 0.612       | 0.903   | 0.852   | 0.863   | 0.649   |
|          | 3%/3 mm     | 0.558       | 0.873   | 0.887   | 0.947   | 0.649   |
|          | 5%/3 mm     | 0.235       | 0.349   | 0.306   | 0.531   | 0.526   |
| \( \gamma_{\text{local}} \)  | 1%/1 mm     | 2%/2 mm     | 2%/3 mm | 3%/2 mm | 3%/3 mm | 5%/3 mm |
|          | 0.640       | 0.541       | 0.735   | 0.546   | 0.546   |          |
|          | 2%/2 mm     | 0.841       | 0.853   | 0.952   | 0.808   | 0.720   |
|          | 2%/3 mm     | 0.713       | 0.954   | 0.874   | 0.922   | 0.784   |
|          | 3%/2 mm     | 0.800       | 0.979   | 0.948   | 0.867   | 0.814   |
|          | 3%/3 mm     | 0.680       | 0.928   | 0.977   | 0.957   | 0.872   |
|          | 5%/3 mm     | 0.575       | 0.822   | 0.874   | 0.890   | 0.942   |

(Continues)
| Colour | HT | VMAT |
|--------|----|------|
| D&C   | [1%HD…]/1 mm | 0.533 | 0.410 | 0.456 | 0.328 | 0.172 |
|        | [2%HD…]/2 mm | 0.763 | 0.722 | 0.753 | 0.562 | 0.256 |
|        | [3%HD…]/3 mm | 0.685 | 0.936 | 0.775 | 0.781 | 0.363 |
|        | [5%HD…]/3 mm | 0.700 | 0.915 | 0.903 | 0.753 | 0.324 |
|        | [1%HD…]/1 mm | 0.617 | 0.802 | 0.885 | 0.899 | 0.437 |
|        | [2%HD…]/2 mm | 0.294 | 0.397 | 0.475 | 0.537 | 0.667 |
| MADD₀ | 1%/1 mm | 0.746 | 0.861 | 0.695 | 0.693 | 0.112 |
|        | 2%/2 mm | 0.972 | 0.993 | 0.713 | 0.793 | 0.116 |
|        | 3%/2 mm | 0.012 | 0.028 | 0.029 | 0.817 | 0.198 |
|        | 5%/3 mm | 0.189 | 0.279 | 0.292 | 0.018 | 0.529 |
| MADDᵧ | 1%/1 mm | 0.090 | 0.056 | 0.091 | 0.054 | 0.184 |
|        | 2%/2 mm | 0.746 | 0.861 | 0.695 | 0.693 | 0.112 |
|        | 3%/2 mm | 0.012 | 0.028 | 0.029 | 0.817 | 0.198 |
|        | 5%/3 mm | 0.189 | 0.279 | 0.292 | 0.018 | 0.529 |

S’id’ak corrected significance level $\alpha_{id} = 0.005$, $p_{id}$ in all cases except for HT where 2%/2 mm: $p_{id}$ (D&C vs. $G_{global}$) = 0.014, 2%/3 mm: $p_{id}$ (D&C vs. $G_{global}$) = 0.008, 3%/2 mm: $p_{id}$ (MADD₀ vs. MADD₀) = 0.061, 5%/3 mm: $p_{id}$ (MADD₀ vs. MADD₀) = 0.039, 5%/3 mm: $p_{id}$ (MADD₀ vs. D&C) = 0.008 and for VMAT where 3%/3 mm: $p_{id}$ (MADDᵧ vs. $G_{global}$) = 0.152, 3%/3 mm: $p_{id}$ (MADDᵧ vs. MADD₀) = 0.090.

---

**Table A5 R² for relationship between %GP/BAI of one particular dose comparison technique and other dose comparison techniques. Tomotherapy results in lower left, VMAT results in upper right**

|          | HT   | VMAT |
|----------|------|------|
| 1%/1 mm  | $G_{global}$ | 0.488 | 0.585 | 0.124 | 0.037 |
|          | Glocal | 0.684 | 0.642 | 0.002 | 0.043 |
|          | D&C[1%HD…]/1 mm | 0.844 | 0.657 | 0.005 | 0.014 |
|          | MADD₀ | 0.808 | 0.537 | 0.765 | 0.796 |
|          | MADDᵧ | 0.813 | 0.534 | 0.721 | 0.959 |
| 2%/2 mm  | $G_{global}$ | 0.652 | 0.538 | 0.133 | 0.009 |
|          | Glocal | 0.690 | 0.404 | 0.043 | 0.626 |
|          | D&C[2%HD…]/2 mm | 0.868 | 0.652 | 0.043 | 0.001 |
|          | MADD₀ | 0.844 | 0.567 | 0.717 | 0.943 |
|          | MADDᵧ | 0.874 | 0.627 | 0.751 |
| HT       | VMAT    | D&C | MADDb | MADDγ |
|----------|---------|-----|-------|-------|
| 2%3 mm   | Gglobal | 0.642 | 0.465 | 0.168 | 0.060 |
|          | Glocal  | 0.702 | 0.306 | 0.049 | 0.005 |
|          | D&C(2%HD…)/3 mm | 0.866 | 0.635 | 0.029 | 0    |
|          | MADDb   | 0.879 | 0.592 | 0.756 | 0.637 |
|          | MADDγ   | 0.918 | 0.657 | 0.786 | 0.955 |
| 3%2 mm   | Gglobal | 0.602 | 0.629 | 0.300 | 0.135 |
|          | Glocal  | 0.613 | 0.390 | 0.127 | 0.058 |
|          | D&C(3%HD…)/2 mm | 0.830 | 0.622 | 0.124 | 0.038 |
|          | MADDb   | 0.025 | 0.012 | 0.019 | 0.661 |
|          | MADDγ   | 0.824 | 0.610 | 0.713 | 0.029 |
| 3%3 mm   | Gglobal | 0.500 | 0.473 | 0.202 | 0    |
|          | Glocal  | 0.611 | 0.261 | 0.104 | 0    |
|          | D&C(3%HD…)/3 mm | 0.773 | 0.574 | 0.041 | 0    |
|          | MADDb   | 0.812 | 0.457 | 0.586 | 0.002 |
|          | MADDγ   | 0.875 | 0.609 | 0.641 | 0.854 |
| 5%3 mm   | Gglobal | 0.516 | 0.288 | 0.122 | 0.137 |
|          | Glocal  | 0.224 | 0.216 | 0.088 | 0.131 |
|          | D&C(5%HD…)/3 mm | 0.395 | 0.253 | 0.191 | 0.078 |
|          | MADDb   | 0.784 | 0.251 | 0.374 | 0.396 |
|          | MADDγ   | 0.841 | 0.362 | 0.324 | 0.829 |